Le informazioni riportate hanno solo fine illustrativo e divulgativo, sono prive di fini pubblicitari e si ricorda che in caso di patologie o disturbi necessario un consulto medico prima di intraprendere qualsiasi terapia
*Correspondence: Menghua Dai [email protected] Zhao [email protected] This article was submitted to Gastrointestinal Cancers, a section of the journal Frontiers in Oncology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
13,216,217 The most relevant challenges can be summarized as follows
Interestingly, a recent study reported a greater exposure to crizotinib and its active metabolite PF-06260182 in subjects with severe renal impairment (creatinine clearance 25%) were increased AST/ALT, lymphopenia, increased ALP, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia